Notable Upgrades: CEL-SCI Corp. (CVM), Synthetic Biologics (SYN), Mavenir Systems (MVNR), Tracon Pharma (TCON), Zioppharm Oncology (ZIOP)

Analysts at Dawson James initiated coverage on CEL-SCI Corporation (CVM) with an ‘Buy’ rating and a $3.00 price target in a research report issued to clients on Monday.

CVM shares recently gained $0.07 to $1.11. In the past 52 weeks, shares of Vienna, Virginia-based drug research company have traded between a low of $0.54 and a high of $1.90. Shares are down 6.31% year-over-year ; up 79.31% year-to-date.

Synthetic Biologics Inc. (SYN) was reiterated a ‘Buy’ by Maxim Group analysts on Monday. The broker also cut its price target on the stock to $3.00 from $6.00.

SYN shares recently gained $0.09 to $2.41. The stock is down more than 15% year-over-year and has gained roughly 59% year-to-date. In the past 52 weeks, shares of Rockville, Maryland-based biotechnology company have traded between a low of $1.16 and a high of $3.64.

Synthetic Biologics Inc. closed Friday at $2.32. The name has a total market cap of $174.76 million.

Mavenir Systems, Inc. (MVNR) was reiterated as ‘Buy’ with a $17 from $16 price target on Monday by Needham.

MVNR shares recently gained $2.28 to $16.85. In the past 52 weeks, shares of Richardson, Texas-based company have traded between a low of $9.36 and a high of $18.78. Shares are down 2.80% year-over-year ; up 7.45% year-to-date.

Tracon Pharmaceuticals, Inc. (TCON) rating of ‘Buy’ was reiterated today at Stifel with a price target decrease of $20 from $16 (versus a $13.43 previous close).

Tracon Pharmaceuticals, Inc., currently valued at $223.25 million, has a median Wall Street price target of $19.00 with a high target of $22.00. Approximately 639K shares have already changed hands, compared to the stock’s average daily volume of 153.72K.

In the past 52 weeks, shares of San Diego, California-based biopharmaceutical company have traded between a low of $9.02 and a high of $20.18 with the 50-day MA and 200-day MA located at $10.32 and $10.32 levels, respectively.

TCON currently prints a year-to-date return of around 97%.

Shares of Zioppharm Oncology, Inc. (ZIOP) are up $0.37, or 2.85%, to $11.63 in mid-day trading after Mizuho reiterated its ‘Buy’ rating and increased its 12-month base case estimate on the name by 3 points to $14 a share.

ZIOP shares recently gained $0.31 to $11.57. In the past 52 weeks, shares of Boston, Massachusetts-based biotech company have traded between a low of $2.31 and a high of $12.19. Shares are up 145.85% year-over-year and 122.09% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*